InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

- Current share price for DXB : $0.220

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$132 Proposed issue of securities - DXB 4 May 2023 9:04AM $0.097 $0.220 risen by 126.80%
$132 Proposed issue of securities - DXB 4 May 2023 9:04AM $0.097 $0.220 risen by 126.80%
$132 Proposed issue of securities - DXB 4 May 2023 9:04AM $0.097 $0.220 risen by 126.80%
$132 Proposed issue of securities - DXB 4 May 2023 9:04AM $0.097 $0.220 risen by 126.80%
$132 Entitlement offer and Convertible Note to raise $12 million 4 May 2023 9:04AM $0.097 $0.220 risen by 126.80%
$132 Voluntary Suspension 3 May 2023 8:44AM $0.097 $0.220 risen by 126.80%
$132 Initial Director's Interest Notice - CS 2 May 2023 3:42PM $0.097 $0.220 risen by 126.80%
$132 Dimerix Announces New Board Member 1 May 2023 9:07AM $0.097 $0.220 risen by 126.80%
$132 Trading Halt 1 May 2023 8:47AM $0.097 $0.220 risen by 126.80%
$132 Quarterly Appendix 4C and Activities Report 28 Apr 2023 4:47PM $0.097 $0.220 risen by 126.80%
$132 Ceasing to be a substantial holder 21 Apr 2023 12:56PM $0.100 $0.220 risen by 120%
$132 FSGS Study, Partnering & Commercialisation Investor Briefing 22 Mar 2023 8:41AM $0.110 $0.220 risen by 100%
$132 Half-Year Financial Report & Appendix 4D - 31 December 2022 27 Feb 2023 8:35AM $0.120 $0.220 risen by 83.33%
$132 DXB to Receive $2.8m in Prepayment of R&D Tax Incentive 17 Feb 2023 8:32AM $0.120 $0.220 risen by 83.33%
$132 Successful Completion of DSMB Review of Phase 3 FSGS Trial 9 Feb 2023 9:04AM $0.135 $0.220 risen by 62.96%
$132 Quarterly Appendix 4C and Activities Report 31 Jan 2023 8:45AM $0.140 $0.220 risen by 57.14%
$132 FDA Confirms Inclusion of Paediatrics in ACTION3 Study 12 Jan 2023 9:16AM $0.150 $0.220 risen by 46.67%
$132 Final Director's Interest Notice 28 Dec 2022 10:29AM $0.155 $0.220 risen by 41.94%
$132 Resignation of Non-Executive Chairman 23 Dec 2022 9:24AM $0.155 $0.220 risen by 41.94%
$132 DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved 15 Dec 2022 8:55AM $0.150 $0.220 risen by 46.67%
$132 CLARITY 2.0 COVID-19 Study Outcome 13 Dec 2022 8:46AM $0.165 $0.220 risen by 33.33%
$132 Constitution 29 Nov 2022 3:19PM $0.165 $0.220 risen by 33.33%
$132 Results of Meeting 29 Nov 2022 3:16PM $0.165 $0.220 risen by 33.33%
$132 Chair address and CEO presentation to AGM 29 Nov 2022 9:16AM $0.160 $0.220 risen by 37.50%
$132 Investor Briefing 23 Nov 2022 8:36AM $0.150 $0.220 risen by 46.67%

326 - 350 of 739 results

Page 14 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.